^
    18h
    PBCAR0191-01: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P1, N=135, Recruiting, Imugene Limited | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • azercabtagene zapreleucel (PBCAR0191)
    21h
    Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. (PubMed, Adv Ther)
    Successful fixed-duration regimens in CLL should achieve deep remission (i.e., undetectable minimal residual disease), sustain long-term progression-free survival, decrease the burden of treatment-related adverse events, and allow for re-treatment with minimal risk of drug resistance. Although fixed-duration treatment represents a positive step forward for most patients with CLL/SLL, the currently approved regimens often fall short in patients at high risk of progression. Continued research and development of next-generation drugs is essential to enhance efficacy and safety, ultimately improving outcomes in all patients with CLL/SLL.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    3d
    An Open-Label, Single-Arm Study of Sonrotoclax Plus Zanubrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without Disease Progression After First-Line BTK Inhibitor Therapy. (ChiCTR2500111878)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    3d
    A Phase III, Open-Label, Randomized Study of HBW-3220 Capsules Compared to Investigator's Choice in Participants With Relapsed/​Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Bruton Tyrosine Kinase (BTK) Inhibitors (ChiCTR2500114564)
    P3, N=216, Not yet recruiting, Chinese Academy of Medical Sciences Hospital of Hematology; Hyperway Pharmaceutical Co.,Ltd.
    New P3 trial
    |
    Rituxan (rituximab) • bendamustine
    4d
    Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=15, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV
    5d
    VENETOSTOP: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Enrollment closed • Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ
    |
    Venclexta (venetoclax)
    5d
    BRUIN CLL-322: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, Loxo Oncology, Inc. | Trial primary completion date: Apr 2026 --> Oct 2026 | Trial completion date: Jan 2027 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib) • Truxima (rituximab-abbs)
    6d
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    6d
    BGB-3111-215t: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (clinicaltrials.gov)
    P2, N=96, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    7d
    Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide
    7d
    BRUIN: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
    P1/2, N=803, Completed, Loxo Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Dec 2025
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
    8d
    PRT2527-02: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies (clinicaltrials.gov)
    P1, N=86, Completed, Prelude Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • PRT2527